These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12038303)

  • 21. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
    Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
    J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals.
    Costagliola D; Potard V; Duvivier C; Pradier C; Dupont C; Salmon D; Duval X;
    Antivir Ther; 2005; 10(4):563-73. PubMed ID: 16038483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Class-sparing treatment therapies.
    Proj Inf Perspect; 1999 Apr; (27):5-6. PubMed ID: 11366740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV protease inhibitors: pharmacologic and metabolic distinctions.
    Sommadossi JP
    AIDS; 1999 Sep; 13 Suppl 1():S29-40. PubMed ID: 10546783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
    Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
    AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.
    Tamalet C; Fantini J; Tourres C; Yahi N
    AIDS; 2003 Nov; 17(16):2383-8. PubMed ID: 14571191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Options for first line therapy.
    Proj Inf Perspect; 1999 Apr; (27):7-8. PubMed ID: 11366741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The psychology of compliance.
    Condor B
    Posit Aware; 1997; 8(2):18-20. PubMed ID: 11364453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Directions for HIV research.
    Learned J
    Posit Aware; 2000; 11(1):32-5. PubMed ID: 11366348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding and managing resistance.
    Berger DS
    Posit Aware; 1998; 9(1):21. PubMed ID: 11364997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.